Regeneron Pharmaceuticals
Regeneron’s High-Dose Eylea Launch Takes Off, Rivals Roche’s Vabysmo
Roche’s increased sales for its extended-release treatment for macular degeneration, Vabysmo, indicate that consumers are willing to try new therapies. ...
Dupixent Fails to Win FDA Approval for Hives Disorder, Needs More Data
Regeneron and Sanofi have faced an unexpected hurdle in their pursuit of regulatory approval for Dupixent, a monoclonal antibody aimed ...
Debbie Allen joins Regeneron and Prevent Blindness to launch the Gr8 Eye Movement and raise awareness of serious retinal diseases
Regeneron is adding a touch of star power to its efforts to promote eye health by enlisting the renowned actress, ...
EMA Accepts Filing for Odronextamab to Address Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Regeneron Pharmaceuticals achieved a significant milestone with the European Medicines Agency (EMA) accepting the Marketing Authorization Application (MAA) for odronextamab, ...
FDA Grants Landmark Approval to Veopoz for the Treatment of Pediatric and Adult CHAPLE Disease
On August 18, 2023, Regeneron Pharmaceuticals announced a remarkable milestone. The US Food and Drug Administration (FDA) has granted approval ...
FDA Approves Eylea HD Injection 8 mg for the Treatment of Wet Age-related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy
On August 18, 2023, Regeneron Pharmaceuticals announced a groundbreaking development in the field of ophthalmology: the US Food and Drug ...
Regeneron Faces New Challenges as Biosimilars Target Eylea Market Dominance, Novartis’ Sandoz Takes Aim with Therapeutic Equivalence
Regeneron finds itself at a crossroads as its blockbuster eye drug Eylea contends with an FDA rejection and growing competition ...
Regeneron’s High-Dose Eylea Demonstrates Persistence as FDA Decision Looms
While awaiting an FDA decision regarding a higher-dose version of Eylea (aflibercept), Regeneron has consistently emphasized the durability of their ...
Catalent’s Indiana Facility Faces FDA Observations After Eylea Rejection
Following an unexpected rejection from the FDA for Regeneron’s high-dose Eylea, the FDA disclosed issues related to cleaning and procedures ...
